RT Journal Article SR Electronic T1 A sensitive and rapid wastewater test for SARS-COV-2 and its use for the early detection of a cluster of cases in a remote community JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.08.13.21262039 DO 10.1101/2021.08.13.21262039 A1 Jade Daigle A1 Kathleen Racher A1 Justin Hazenberg A1 Allan Yeoman A1 Heather Hannah A1 Diep Duong A1 Umar Mohammed A1 Dave Spreitzer A1 Branden S. J. Gregorchuk A1 Breanne M. Head A1 Adrienne F.A. Meyers A1 Paul A. Sandstrom A1 Anil Nichani A1 James I. Brooks A1 Michael R. Mulvey A1 Chand S. Mangat A1 Michael G. Becker YR 2021 UL http://medrxiv.org/content/early/2021/08/18/2021.08.13.21262039.abstract AB Throughout the COVID-19 pandemic, wastewater surveillance has been used to monitor trends in SARS-CoV-2 prevalence in the community. A major challenge in establishing wastewater surveillance programs, especially in remote areas, is the need for a well-equipped laboratory for sample analysis. Currently, no options exist for rapid, sensitive, mobile, and easy-to-use wastewater tests for SARS-CoV-2. The performance of the GeneXpert System, which offers cartridge-based, rapid molecular clinical testing for SARS-CoV-2 in a portable platform, was evaluated using wastewater as the input. The GeneXpert demonstrated a SARS-CoV-2 limit of detection in wastewater below 32 copies/mL with a sample processing time of less than an hour. Using wastewater samples collected from multiple sites across Canada during February and March 2021, a high overall agreement (97.8%) was observed between the GeneXpert assay and laboratory-developed tests regarding the presence or absence of SARS-CoV-2. Additionally, with the use of centrifugal filters the detection threshold of the GeneXpert system was improved to <10 copies/mL in wastewater. Finally, to support on-site wastewater surveillance, GeneXpert testing was implemented in Yellowknife, a remote community in Northern Canada where its use successfully alerted public health authorities to undetected transmission of COVID-19. The identification of SARS-CoV-2 in wastewater triggered clinical testing of recent travelers and identification of new COVID-19 cases/clusters. Taken together, these results suggest the GeneXpert is a viable option for surveillance of SARS-CoV-2 in wastewater in locations that do not have access to established testing laboratories.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study did not involve clinical specimens.Funding StatementExperiments were funded and supported by the Public Health Agency of Canada and Government of the Northwest Territories.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study did not involve clinical specimens, and tested environmental/wastewater samples for SARS-CoV-2.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript.